U.S. Government Revamps Economic Strategy: The New Era of Dealmaking

The Trump administration is actively forming deals with pharmaceutical companies and over 30 other industries to ensure economic and national security. This strategic shift involves offering tariff relief and financial incentives, aiming for political gains before the 2026 midterm elections. A significant role is played by the International Development Finance Corporation, proposing a $250 billion funding increase to stabilize critical sectors. Critics argue this state-centric approach contradicts free-market principles.

The Trump administration is moving rapidly with a new strategy to bolster the U.S. economy through significant deals across over 30 sectors, including top pharmaceutical firms like Eli Lilly, Pfizer, and AstraZeneca.

According to insiders, this initiative offers tariff relief and other incentives to secure political wins before the 2026 midterm elections. The International Development Finance Corporation is a key player, with a proposal to expand its $250 billion fund aiming to stabilize vital industries.

Critics warn that such a strategy contradicts the traditional free-market ethos, with concerns over government interference in picking sector winners. However, the administration sees these steps as safeguarding U.S. interests, enhancing domestic manufacturing, and reducing dependence on foreign resources.

(With inputs from agencies.)